GLPG
Galapagos N.V. NASDAQ Listed Feb 27, 2012$27.98
+1.71%
vs $27.51
Mkt Cap $1.8B
52w Low $24.74
24.8% of range
52w High $37.78
50d MA $30.32
200d MA $32.15
P/E (TTM)
3.8x
EV/EBITDA
-4.8x
P/B
0.6x
Debt/Equity
0.0x
ROE
—
P/FCF
-9.9x
RSI (14)
66.90
ATR (14)
$0.63
Beta
0.15
50d MA
$30.32
200d MA
$32.15
Avg Volume
178.5K
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Generaal De Wittelaan L11 A3 · Mechelen, C9 2800 · BE
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | -1.14 | 0.25 | +122.0% | 28.81 | -1.0% | -3.7% | +3.1% | -4.0% | -0.4% | +3.0% | — |
| Feb 23, 2026 | AMC | 1.00 | 16.38 | +1538.0% | 33.87 | +5.5% | +1.4% | -1.0% | -1.6% | +0.5% | +1.3% | — |
| Nov 5, 2025 | AMC | -0.20 | -3.59 | -1696.3% | 29.89 | +1.7% | +4.4% | +1.1% | +2.9% | +1.2% | -1.6% | — |
| Jul 23, 2025 | AMC | -0.67 | -1.89 | -182.3% | 33.29 | -13.4% | -7.3% | +5.8% | +0.4% | +0.1% | +1.4% | — |
| Apr 23, 2025 | AMC | -0.23 | -2.47 | -973.9% | 25.50 | +0.2% | +3.9% | +1.4% | +0.0% | +0.2% | +0.0% | — |
| Feb 28, 2025 | AMC | -0.24 | 0.39 | +263.3% | 26.08 | +2.5% | -0.3% | -1.0% | +1.3% | +1.9% | +0.1% | — |
| Oct 30, 2024 | AMC | -0.27 | -0.77 | -185.2% | 28.59 | -5.8% | -7.5% | +1.7% | -0.7% | +0.1% | +1.0% | — |
| Sep 12, 2024 | AMC | 0.03 | 0.14 | +450.3% | 29.30 | +0.5% | +2.9% | +1.7% | -0.4% | -0.9% | +0.5% | — |
| May 2, 2024 | AMC | -0.12 | 0.39 | +425.0% | 29.45 | -1.2% | -1.2% | +1.3% | -1.3% | -0.2% | -0.9% | — |
| Feb 23, 2024 | AMC | -1.18 | 2.39 | +302.5% | 36.24 | -0.0% | +0.7% | +0.7% | -1.8% | -2.7% | +0.0% | — |
| Nov 3, 2023 | AMC | -0.62 | 0.39 | +162.9% | 37.06 | +5.0% | +2.8% | -0.1% | -3.6% | -1.2% | +0.2% | — |
| Aug 3, 2023 | AMC | -0.70 | 0.08 | +111.4% | 42.20 | +4.2% | +0.4% | -4.6% | -3.6% | -0.6% | +2.4% | — |
| May 4, 2023 | AMC | -0.87 | 0.43 | +149.4% | 40.50 | +2.9% | +5.9% | -2.1% | -0.3% | +0.1% | -1.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $34.36 | $34.42 | +0.2% | -1.0% | -1.6% | +0.5% | +1.3% | -3.1% |
| Nov 7 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $31.20 | $31.91 | +2.3% | +1.1% | +2.9% | +1.2% | -1.6% | -2.5% |
| Oct 22 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $31.43 | $32.19 | +2.4% | +1.4% | +0.5% | -0.2% | -2.8% | +0.9% |
| Oct 21 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $34.39 | $32.05 | -6.8% | -8.6% | +1.4% | +0.5% | -0.2% | -2.8% |
| Feb 14 | Morgan Stanley | Downgrade | Equal Weight → Underweight | — | $25.49 | $25.15 | -1.3% | -0.2% | +4.3% | +0.6% | +0.1% | +0.0% |
| Jan 23 | Barclays | Downgrade | Equal Weight → Underweight | — | $23.93 | $23.56 | -1.5% | -0.8% | -0.2% | -0.4% | -0.5% | -1.4% |
| Nov 1 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $26.44 | $26.75 | +1.2% | +1.7% | -0.7% | +0.1% | +1.0% | +1.7% |
| Apr 22 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $29.08 | $28.96 | -0.4% | -0.0% | +1.3% | -2.3% | -0.5% | +0.5% |
| Apr 1 | BofA Securities | Downgrade | Neutral → Underperform | — | $32.20 | $32.06 | -0.4% | +0.9% | -2.2% | +0.1% | +0.1% | +0.0% |
| Mar 28 | BofA Securities | Downgrade | Neutral → Underperform | — | $32.95 | $32.18 | -2.3% | -2.3% | +0.9% | -2.2% | +0.1% | +0.1% |
| Jan 2 | BofA Securities | Maintains | Neutral → Neutral | — | $40.65 | $40.60 | -0.1% | +1.7% | -0.4% | +0.6% | -0.3% | +2.8% |
| Aug 7 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $42.36 | $42.42 | +0.1% | -4.6% | -3.6% | -0.6% | +2.4% | -0.9% |
| Aug 1 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $42.35 | $42.00 | -0.8% | -0.8% | -0.5% | +1.0% | +0.4% | -4.6% |
| Jul 31 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $41.82 | $41.57 | -0.6% | +1.3% | -0.8% | -0.5% | +1.0% | +0.4% |
| Jul 24 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $42.98 | $42.48 | -1.2% | -2.1% | -2.2% | -0.3% | -1.5% | +3.5% |
| Jul 17 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $41.79 | $42.34 | +1.3% | +0.3% | +1.4% | +0.4% | -0.2% | +0.9% |
| Jun 26 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $41.00 | $41.22 | +0.5% | -1.1% | +1.0% | -1.5% | +0.2% | +0.7% |
| Jun 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $43.04 | $41.40 | -3.8% | -1.9% | -0.4% | -1.1% | +2.0% | -0.1% |
| May 31 | JP Morgan | Maintains | Neutral → Neutral | — | $42.14 | $41.35 | -1.9% | -1.9% | -0.9% | +1.1% | +0.9% | +1.3% |
| May 9 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $41.99 | $41.18 | -1.9% | -0.3% | +0.1% | -1.7% | -1.6% | +3.7% |
| May 8 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $42.89 | $42.60 | -0.7% | -2.1% | -0.3% | +0.1% | -1.7% | -1.6% |
| May 8 | Raymond James | Upgrade | Market Perform → Outperform | — | $42.89 | $42.60 | -0.7% | -2.1% | -0.3% | +0.1% | -1.7% | -1.6% |
| Feb 27 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $38.19 | $38.03 | -0.4% | -1.2% | -0.6% | +0.4% | -2.6% | +0.5% |
| Feb 27 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $38.19 | $38.03 | -0.4% | -1.2% | -0.6% | +0.4% | -2.6% | +0.5% |
| Jan 23 | Jefferies | Upgrade | Underperform → Hold | — | $45.82 | $47.06 | +2.7% | +0.9% | -2.5% | -1.1% | +0.1% | -0.9% |
| Nov 7 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $42.75 | $41.09 | -3.9% | -3.5% | -0.3% | -2.5% | +3.4% | +0.8% |
| Nov 7 | Raymond James | Downgrade | Outperform → Market Perform | — | $42.75 | $41.09 | -3.9% | -3.5% | -0.3% | -2.5% | +3.4% | +0.8% |
| Nov 7 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $42.75 | $41.09 | -3.9% | -3.5% | -0.3% | -2.5% | +3.4% | +0.8% |
| Oct 13 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $42.10 | $41.90 | -0.5% | +2.6% | +0.6% | +2.6% | +2.3% | -3.7% |
| Sep 9 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $48.57 | $48.80 | +0.5% | -0.8% | +8.0% | -5.4% | -0.4% | -0.8% |
| Aug 15 | Morgan Stanley | Maintains | Overweight → Overweight | — | $54.25 | $54.56 | +0.6% | +1.7% | -1.0% | -1.7% | -2.7% | -0.2% |
| Aug 8 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $54.70 | $54.56 | -0.3% | -1.1% | -1.5% | +2.5% | -0.8% | +0.1% |
| Jul 15 | Morgan Stanley | Maintains | Overweight → Overweight | — | $52.89 | $53.32 | +0.8% | +1.7% | +0.4% | +4.9% | -0.4% | -0.3% |
| May 9 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $59.66 | $59.31 | -0.6% | -5.2% | +2.1% | -1.9% | +1.1% | +3.4% |
| Feb 28 | Morgan Stanley | Maintains | Overweight → Overweight | — | $65.74 | $65.39 | -0.5% | +0.7% | +0.1% | -2.8% | -3.8% | -0.8% |
| Jan 27 | Citigroup | Upgrade | Neutral → Buy | — | $53.32 | $61.63 | +15.6% | +22.5% | +3.3% | +0.1% | +1.5% | -4.1% |
| Jan 6 | Morgan Stanley | Maintains | Overweight → Overweight | — | $51.75 | $52.09 | +0.7% | +0.2% | -0.0% | -1.0% | +2.1% | -0.7% |
| Nov 8 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $54.28 | $55.96 | +3.1% | +5.2% | -1.2% | -3.8% | -1.6% | -1.1% |
| Aug 19 | Barclays | Downgrade | Overweight → Equal Weight | — | $59.07 | $57.78 | -2.2% | -4.4% | -1.9% | +3.4% | -0.3% | -0.2% |
| Aug 9 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $60.14 | $58.87 | -2.1% | -1.1% | -0.5% | -1.1% | +0.6% | -0.3% |
| May 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $75.04 | $71.11 | -5.2% | -2.0% | +0.1% | +0.7% | +2.6% | +0.2% |
| Apr 14 | Barclays | Upgrade | Equal Weight → Overweight | — | $78.30 | $81.51 | +4.1% | +2.8% | -1.4% | -0.3% | -0.4% | +1.1% |
| Mar 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $82.41 | $83.28 | +1.1% | +1.3% | -1.3% | +0.8% | -1.4% | -1.6% |
| Feb 22 | Raymond James | Upgrade | Market Perform → Outperform | — | $86.28 | $83.56 | -3.2% | -0.7% | -0.4% | -0.9% | +0.6% | -3.0% |
| Jan 19 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $100.01 | $106.53 | +6.5% | +7.7% | +0.7% | +3.2% | -0.7% | +0.1% |
| Nov 19 | Maxim Group | Maintains | Buy → Buy | — | $123.95 | $123.01 | -0.8% | -0.5% | +1.0% | +0.5% | -1.4% | -2.2% |
| Oct 21 | Goldman Sachs | Downgrade | Neutral → Sell | — | $131.79 | $123.35 | -6.4% | -6.6% | +0.5% | +3.2% | -0.3% | +0.6% |
| Oct 13 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $148.25 | $147.01 | -0.8% | -1.6% | -2.2% | -2.8% | -7.0% | +1.2% |
| Aug 25 | Jefferies | Downgrade | Buy → Hold | — | $134.83 | $129.64 | -3.8% | -2.3% | +1.8% | -2.8% | +0.4% | +1.7% |
| Aug 24 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $137.16 | $136.48 | -0.5% | -1.7% | -2.3% | +1.8% | -2.8% | +0.4% |
No insider trades available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Gilead Sciences, Inc. | 16,707,477 | $551M | — | Dec 2025 |
| 2 | Tang Capital Management Llc | 3,921,219 | $128M | Reduced | Dec 2025 |
| 3 | Segall Bryant & Hamill, Llc | 426,412 | $13M | New | Mar 2026 |
| 4 | Point72 Asset Management | 332,125 | $10M | Reduced | Mar 2026 |
| 5 | Renaissance Technologies Llc | 315,400 | $9M | Added | Mar 2026 |
| 6 | Greenlight Capital | 162,578 | $7M | Added | Dec 2023 |
| 7 | D.e. Shaw & Co | 215,718 | $6M | Reduced | Mar 2026 |
| 8 | Hudson Bay Capital Management Lp | 170,000 | $6M | Reduced | Dec 2025 |
| 9 | Ubs Group Ag | 175,289 | $5M | Reduced | Mar 2026 |
| 10 | Morgan Stanley | 136,570 | $4M | Added | Dec 2025 |
| 11 | Citadel Advisors Llc | 124,428 | $4M | Added | Mar 2026 |
| 12 | Millennium Management | 107,912 | $3M | Reduced | Mar 2026 |
| 13 | Man Group Plc | 80,209 | $2M | Added | Mar 2026 |
| 14 | Acadian Asset Management Llc | 45,942 | $1M | Added | Mar 2026 |
| 15 | Hrt Financial Lp | 45,168 | $1M | New | Mar 2026 |
| 16 | Barometer Capital Management Inc. | 38,100 | $1M | Added | Mar 2026 |
| 17 | Monaco Asset Management Sam | 32,520 | $1M | Reduced | Dec 2025 |
| 18 | Two Sigma Investments, Lp | 25,860 | $776K | Added | Mar 2026 |
| 19 | Bank Of America Corp /de/ | 20,725 | $622K | Reduced | Mar 2026 |
| 20 | Prelude Capital Management, Llc | 19,305 | $579K | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 16
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Columbia Overseas Value Fund | 714,747 | $24M | Feb 2026 |
| 2 | iShares Biotechnology ETF | 271,893 | $8M | Mar 2026 |
| 3 | Columbia Overseas Core Fund | 90,697 | $3M | Feb 2026 |
| 4 | ALPS Medical Breakthroughs ETF | 58,387 | $2M | Feb 2026 |
| 5 | Schwab International Opportunities Fund | 32,701 | $1M | Jan 2026 |
| 6 | Avantis International Equity ETF | 30,449 | $1M | Feb 2026 |
| 7 | International Value Fund | 26,834 | $903K | Feb 2026 |
| 8 | ActivePassive International Equity ETF | 14,120 | $475K | Feb 2026 |
| 9 | Fidelity Nasdaq Composite Index Fund | 7,851 | $264K | Feb 2026 |
| 10 | Avantis International Small Cap Equity ETF | 5,712 | $192K | Feb 2026 |
| 11 | Columbia Global Opportunities Fund | 3,569 | $121K | Jan 2026 |
| 12 | Goldman Sachs Innovate Equity ETF | 3,048 | $87K | May 2026 |
| 13 | Avantis International Equity Fund | 1,419 | $48K | Feb 2026 |
| 14 | Invesco Nasdaq Biotechnology ETF | 803 | $27K | Feb 2026 |
| 15 | ProShares Ultra Nasdaq Biotechnology | 668 | $22K | Feb 2026 |
| 16 | Xtrackers MSCI Eurozone Hedged Equity ETF | 308 | $10K | Feb 2026 |
Valuation
Market Cap
$1.84B
Enterprise Value
-$994.3M
P/E (TTM)
3.77x
Forward P/E
—
PEG Ratio
0.02x
P/B
0.57x
P/S
1.77x
P/FCF
-9.89x
EV/EBITDA
-4.82x
Shares Out
65.9M
Financials (TTM)
Revenue
$1.04B
Net Income
$488.8M
EBITDA
$206.1M
Free Cash Flow
-$202.4M
Op Cash Flow
-$189.2M
EPS Basic
$4.85
EPS Diluted
$7.39
EPS Forward
$-2.14
Gross Margin
98.0%
Op Margin
37.5%
Net Margin
46.8%
Balance Sheet
Total Assets
$3.41B
Total Liab.
$170.6M
Total Equity
$3.23B
Cash
$3.00B
LT Debt
$0
Book Value/Sh
$48.87
Debt/Equity
0.00x
Current Ratio
20.15
Quick Ratio
20.15
Returns & Growth
ROE
—
ROA
—
ROIC
15.4%
Rev Growth YoY
+303.5%
EPS Growth YoY
+333.0%
Price Returns
2W
+7.1%
1M
-0.5%
3M
-4.8%
6M
-15.1%
12M
-1.8%
Technicals
52W High
$37.78
52W Low
$24.74
50d MA
$30.32
200d MA
$32.15
RSI (14)
66.90
ATR (14)
$0.63
Beta
0.15
Avg Volume
179K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$33.00
High
$33.00
Low
$33.00
Median
$33.00
Data updated apr 26, 2026 10:41am
· Source: financialmodelingprep.com